Does the media favor EYPT or PCRX?

In the previous week, Pacira BioSciences had 50 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 52 mentions for Pacira BioSciences and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Pacira BioSciences' score of 0.18 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 8 Very Positive mention(s) 11 Positive mention(s) 19 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SPTX or EYPT?

In the previous week, Seaport Therapeutics had 9 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 11 mentions for Seaport Therapeutics and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Seaport Therapeutics' score of 0.09 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EYPT or ANRO?

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Alto Neuroscience. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Alto Neuroscience's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EYPT or SGP?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Spyglass Pharma's average media sentiment score of 1.46 beat Eyepoint Pharmaceuticals' score of 0.46 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eyepoint Pharmaceuticals (EYPT) Competitors

$3.03 -0.04 (-1.40%)

As of 09:57 AM Eastern

Compare

EYPT vs. PCRX, SPTX, ANRO, TBPH, and SGP

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? Eyepoint Pharmaceuticals's main competitors and comparable companies include Pacira BioSciences (PCRX), Seaport Therapeutics (SPTX), Alto Neuroscience (ANRO), Theravance Biopharma (TBPH), and Spyglass Pharma (SGP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eyepoint Pharmaceuticals compare to Pacira BioSciences?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, indicating a potential upside of 737.13%. Pacira BioSciences has a consensus target price of $33.33, indicating a potential downside of 8.20%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Pacira BioSciences	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Pacira BioSciences had 50 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 52 mentions for Pacira BioSciences and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Pacira BioSciences' score of 0.18 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	8 Very Positive mention(s)	11 Positive mention(s)	19 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacira BioSciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.44	-$231.96M	-$3.74	N/A
Pacira BioSciences	$726.41M	1.99	$7.03M	$0.35	103.74

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pacira BioSciences has a net margin of 1.96% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Pacira BioSciences' return on equity of 9.68% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Pacira BioSciences	1.96%	9.68%	5.30%

Summary

Pacira BioSciences beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Seaport Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Seaport Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Seaport Therapeutics' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Seaport Therapeutics has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Eyepoint Pharmaceuticals	$31.37M	8.44	-$231.96M	-$3.74	N/A

In the previous week, Seaport Therapeutics had 9 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 11 mentions for Seaport Therapeutics and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Seaport Therapeutics' score of 0.09 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seaport Therapeutics presently has a consensus price target of $38.57, suggesting a potential upside of 139.87%. Eyepoint Pharmaceuticals has a consensus price target of $25.70, suggesting a potential upside of 737.13%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Seaport Therapeutics beats Eyepoint Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Alto Neuroscience has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.44	-$231.96M	-$3.74	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Alto Neuroscience has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Alto Neuroscience's return on equity of -46.46% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Alto Neuroscience	N/A	-46.46%	-39.09%

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, indicating a potential upside of 737.13%. Alto Neuroscience has a consensus price target of $37.25, indicating a potential upside of 68.32%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Alto Neuroscience. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Alto Neuroscience's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alto Neuroscience beats Eyepoint Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Theravance Biopharma?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Theravance Biopharma has a net margin of 51.58% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Theravance Biopharma's return on equity of -0.77% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 0 mentions for Theravance Biopharma. Eyepoint Pharmaceuticals' average media sentiment score of 0.46 beat Theravance Biopharma's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
Theravance Biopharma	Neutral

Theravance Biopharma has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.44	-$231.96M	-$3.74	N/A
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, indicating a potential upside of 737.13%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 13.92%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Theravance Biopharma beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Spyglass Pharma?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Spyglass Pharma has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Spyglass Pharma is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.44	-$231.96M	-$3.74	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Spyglass Pharma has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Spyglass Pharma's return on equity of -62.40% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Spyglass Pharma	N/A	-62.40%	-24.83%

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Spyglass Pharma's average media sentiment score of 1.46 beat Eyepoint Pharmaceuticals' score of 0.46 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, indicating a potential upside of 737.13%. Spyglass Pharma has a consensus price target of $44.00, indicating a potential upside of 83.95%. Given Eyepoint Pharmaceuticals' higher possible upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Spyglass Pharma beats Eyepoint Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$261.65M	$12.37B	$7.26B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-0.81	658.01	206.66	19.94
Price / Sales	8.32	750.45	562.21	81.34
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.82	9.19	10.75	6.03
Net Income	-$231.96M	$2.83B	$3.50B	$380.34M
7 Day Performance	-8.83%	-3.42%	-2.91%	-2.34%
1 Month Performance	-28.78%	-7.48%	-7.38%	-5.31%
1 Year Performance	-77.00%	-5.63%	2.96%	-2.94%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	2.5573 of 5 stars	$3.03 -1.4%	$25.70 +749.0%	-77.0%	$261.65M	$31.37M	N/A	214
PCRX Pacira BioSciences	2.0447 of 5 stars	$24.92 -0.5%	$30.14 +20.9%	+63.1%	$993.36M	$746.16M	71.20	829
SPTX Seaport Therapeutics	2.7951 of 5 stars	$17.73 -4.2%	$38.57 +117.5%	N/A	$949.09M	N/A	N/A	58	Analyst Forecast
ANRO Alto Neuroscience	1.7338 of 5 stars	$23.94 -0.3%	$37.25 +55.6%	+275.5%	$939.45M	N/A	N/A	68
TBPH Theravance Biopharma	1.7032 of 5 stars	$17.03 flat	$19.40 +13.9%	N/A	$884.18M	$104.31M	16.86	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. PCRX, SPTX, ANRO, TBPH, and SGP

How does Eyepoint Pharmaceuticals compare to Pacira BioSciences?

Summary

How does Eyepoint Pharmaceuticals compare to Seaport Therapeutics?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Summary

How does Eyepoint Pharmaceuticals compare to Theravance Biopharma?

Summary

How does Eyepoint Pharmaceuticals compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. PCRX, SPTX, ANRO, TBPH, and SGP

How does Eyepoint Pharmaceuticals compare to Pacira BioSciences?

Which has more risk and volatility, EYPT or PCRX?

Do analysts prefer EYPT or PCRX?

Does the media favor EYPT or PCRX?

Which has higher valuation and earnings, EYPT or PCRX?

Do insiders & institutionals have more ownership in EYPT or PCRX?

Is EYPT or PCRX more profitable?

Summary

How does Eyepoint Pharmaceuticals compare to Seaport Therapeutics?

Is SPTX or EYPT more profitable?

Which has better valuation & earnings, SPTX or EYPT?

Does the media prefer SPTX or EYPT?

Do analysts prefer SPTX or EYPT?

Do institutionals and insiders hold more shares of SPTX or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Which has better valuation and earnings, EYPT or ANRO?

Is EYPT or ANRO more profitable?

Which has more risk and volatility, EYPT or ANRO?

Do analysts prefer EYPT or ANRO?

Do insiders & institutionals have more ownership in EYPT or ANRO?

Does the media favor EYPT or ANRO?

Summary

How does Eyepoint Pharmaceuticals compare to Theravance Biopharma?

Do institutionals & insiders believe in EYPT or TBPH?

Is EYPT or TBPH more profitable?

Which has more risk & volatility, EYPT or TBPH?

Does the media refer more to EYPT or TBPH?

Which has preferable earnings and valuation, EYPT or TBPH?

Do analysts prefer EYPT or TBPH?

Summary

How does Eyepoint Pharmaceuticals compare to Spyglass Pharma?

Which has better earnings & valuation, EYPT or SGP?

Is EYPT or SGP more profitable?

Does the media favor EYPT or SGP?

Do analysts rate EYPT or SGP?

Do institutionals and insiders have more ownership in EYPT or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools